RT期刊文章在印第安人SR电子T1缺血性和出血性中风(p3.9 - 011)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP p3.9补充92 - 011签证官是15首页 A1扎卡里·王A1比克曼瑞秋A1的史黛西布朗A1奥黛丽现有A1 Hailey Orgas A1艾米丽Gilmore A1劳伦sans A1查尔斯Matouk A1凯文Sheth A1圭多要求年2019 UL //www.ez-admanager.com/content/92/15_supplement/p3.9 - 011. -文摘AB目的:我们的目的是描述美国本土中风人口的人口和临床特点,确定住院病人死亡的预测因子。背景:中风发病率和死亡率的主要原因是在美国。印第安人占总人口的1.5%。多研究研究中风如何影响少数民族。然而,现有的数据在印第安人中风(NA)仍然极其有限。设计/方法:我们评估索赔数据来自加州的急症护理医院2005 - 2011年之间。在美国加州人口最大的NA。使用验证ICD-9代码,我们确定了初级缺血性(AIS)和出血性中风(我)招生和确定并发症和住院并发症。跨种族/民族和我们比较基线特征识别医院死亡率的独立预测指标使用单变量和多变量逻辑回归。结果:我们发现283107中风在加州在2005年和2011年之间。(234471年AIS(83%)和48636年我[17%])。其中,851名(0.3%)NA(包括AIS 698(82%)和我153 [18%])。 For AIS, NA had intermediate prevalence of vascular risk factors, including smoking history (15% vs 18% in Blacks and 11% in Whites, p<0.001) and diabetes (46% vs 48% in Hispanics and 26% in Whites, p<0.001). Native Americans with AIS were least likely to receive palliative care (1% vs 4% in Whites, p<0.001). In ICH, NA had the second highest proportion of chronic kidney disease (13% vs. 17.5% in Blacks and 8.1% in Whites, p<0.001) and the highest proportion of diabetes (41% vs. 37% in Hispanics and 21% in Whites, p<0.001). In-hospital mortality was similar among minorities (4% [AIS], 26% [ICH], p>0.2). In both AIS and ICH, predictors of in-hospital mortality were similar to other minority groups including atrial fibrillation (p=0.002) in AIS and female sex (p=.005) in ICH.Conclusions: Native Americans constitute an important understudied minority population in stroke. NA have high prevalence of modifiable risk factors including diabetes and smoking.Disclosure: Dr. King has nothing to disclose. Dr. Beekman has nothing to disclose. Dr. Brown has received research support from American Heart Association. Dr. Leasure has nothing to disclose. Dr. Orgass has nothing to disclose. Dr. Gilmore has nothing to disclose. Dr. Sansing has nothing to disclose. Dr. Matouk has nothing to disclose. Dr. Sheth has received royalty, license fees, or contractual rights payments from Alva Health. Dr. Sheth has received research support from Biogen, Novartis, Bard, and Hyperfine. Dr. Falcone has nothing to disclose.

map